The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart

Area of Science:

• Molecular Biology
• Cardiovascular Biology
• Oncology

Background:

• RKIP (RAF kinase inhibitor protein) is a dual inhibitor of RAF1 kinase and GRK2 (G protein-coupled receptor kinase 2).
• RKIP's inhibition of RAF1-MAPK pathway acts as a tumor suppressor.
• RKIP's inhibition of GRK2 counteracts GPCR desensitization, offering potential cardioprotection in heart failure.

Purpose of the Study:

• To investigate the net in vivo effect of RKIP's opposing functions: cardioprotective GRK2 inhibition versus detrimental RAF1-MAPK pathway inhibition.
• To elucidate how beneficial GRK2 inhibition can be compromised by concurrent RAF1-MAPK pathway inhibition.
• To identify requirements for developing effective cardioprotective GRK2 inhibitors based on RKIP studies.

Main Methods:

• Review of existing data on RKIP's effects on cardiomyocytes and cardiac function.
• Analysis of next-generation sequencing (NGS) data of the RKIP-induced cardiac transcriptome.
• Evaluation of endogenous and transgenic RKIP effects under cardiac stress conditions.

Main Results:

• GRK2 inhibition by RKIP promotes cardioprotective signaling in isolated cardiomyocytes.
• However, RKIP's inhibition of the pro-survival RAF1-MAPK pathway deteriorates cardiomyocyte viability.
• Endogenous RKIP promotes cardiac fibrosis, and transgenic RKIP induces heart dysfunction, indicating net detrimental effects in vivo.

Conclusions:

• RKIP's dual inhibitory functions create a conflict, where beneficial GRK2 inhibition is overshadowed by detrimental RAF1-MAPK pathway inhibition.
• This leads to adverse cardiac outcomes, including fibrosis and heart dysfunction, under stress.
• Developing selective GRK2 inhibitors that avoid RAF1-MAPK pathway interaction is crucial for effective cardioprotection.